Acadia Pharmaceuticals Inc ACAD

NAS: ACAD | ISIN: US0042251084   24/04/2024
16,59 USD (-0,90%)
(-0,90%)   24/04/2024

12 november 2022 · ACADIA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD · Persbericht

13 mei 2021 · Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD) · Persbericht

22 april 2021 · ACAD Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies ACADIA Pharmaceuticals Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm · Persbericht

22 april 2021 · HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed · Persbericht

20 april 2021 · Pomerantz Law Firm Announces the Filing of a Class Action against Acadia Pharmaceuticals Inc. and Certain Officers - ACAD · Persbericht

6 april 2021 · Ademi LLP Investigates Claims of Securities Fraud against Acadia Pharmaceuticals Inc. · Persbericht

6 april 2021 · HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys · Persbericht

12 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD · Persbericht

10 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD · Persbericht

10 maart 2021 · HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Acadia Pharmaceuticals (ACAD) For Possible Securities Law Violations, Encourages Investors with Losses to Contact Its Attorneys · Persbericht

Mijn selecties